Comparison of metformin and repaglinide monotherapy in the treatment of new onset type 2 diabetes mellitus in China.

Abstract

OBJECTIVE:

This study was designed to compare the effects of metformin and repaglinide on the fasting plasma glucose (FPG) and glycated haemoglobin (HbA1c) in newly diagnosed type 2 diabetes in China.

METHODS:

A total of 107 newly diagnosed type 2 diabetic patients (46 women and 61 men) participated in the study. All patients received 3-month treatment of metformin or repaglinide. Fasting blood glucose and HbA1c were determined at baseline and at the end of the 3-month of treatment.

RESULTS:

FPG and HbA1c decreased in both metformin and repaglinide groups after 3 months treatment (P < 0.01). The reduction of HbA1c was significantly greater in the repaglinide group (P < 0.01). Metformin decreases fasting insulin concentration and HOMA-IR (P < 0.01), and repaglinide improves HOMA-β(P < 0.01). Triglycerides (TG) were reduced in both groups (P < 0.01 in metformin group; P < 0.05 in repaglinide group), but total cholesterol (TC) and low-density lipoprotein (LDL) were decreased only after metformin treatment (P < 0.05).

CONCLUSIONS:

Both repaglinide and metformin were effective in glycaemic control in new onset patients with type 2 diabetes in China. Repaglinide had no effect on insulin sensitivity, but it improved β-cell function.

• Authors: J Ma, L Y Liu, P H Wu, Y Liao, T Tao, W Liu
• Journal: Journal of diabetes research (J Diabetes Res) Vol. 2014 Pg. 294017 ( 2014) ISSN: 2314-6753 [Electronic] England
• PMID: 24772445 (Publication Type: Comparative Study, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)

Chemical References

• Carbamates
• Glycated Hemoglobin A
• Hypoglycemic Agents
• Insulin
• Piperidines
• hemoglobin A1c protein, human
• repaglinide
• Metformin

Topics

• Body Mass Index
• Carbamates (administration & dosage, adverse effects, therapeutic use)
• China
• Combined Modality Therapy
• Diabetes Mellitus, Type 2 (complications, diet therapy, drug therapy, metabolism)
• Diet, Diabetic
• Diet, Reducing
• Drug Monitoring
• Female
• Glycated Hemoglobin (analysis)
• Humans
• Hyperglycemia (prevention & control)
• Hyperlipidemias (prevention & control)
• Hypoglycemic Agents (administration & dosage, adverse effects, therapeutic use)
• Insulin (analysis, metabolism)
• Insulin Resistance
• Insulin Secretion
• Insulin-Secreting Cells (drug effects, metabolism)
• Male
• Metformin (administration & dosage, adverse effects, therapeutic use)
• Middle Aged
• Overweight (complications, diet therapy)
• Piperidines (administration & dosage, adverse effects, therapeutic use)
• Weight Loss (drug effects)